Welcome to the e-CCO Library!

P480: Characteristics of drug-induced lupus 2° to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mañosa M.*1, Corrales G.1, Olivares D.2, Vicuña M.3, Aguas M.4, Busquets D.5, Tosca J.6, Llaό J.7, Mesonero F.8, García-Tejero I.9, Ferreiro R.10, Cabré E.1, Domènech E.1

Created: Wednesday, 20 February 2019, 10:36 AM
P480: Comparison of executive functioning profiles among adults with Crohn's disease and Ulcerative colitis
Year: 2022
Source: ECCO'22
Authors: Zelnik Yovel, D.(1);Meyer, S.(2);Richter, V.(1);Shirin, H.(1);Broide, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P480: Effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced diarrhoea/colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Ibraheim1,2*, M. Samaan1, N. Powell1,2

Created: Thursday, 21 February 2019, 9:14 AM
P480: Goals of treatment: preferences of inflammatory bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. Casellas*1, 2, C. Herrera de Guise1, V. Robles1, E. Navarro1, N. Borruel1

Created: Friday, 22 February 2019, 9:49 AM
P480: The effect of adjuvant therapy (Sinergin®) in induction and maintaining remission in mild and moderate IBD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Ichim*1, A. Dimitriu1, C. Gheorghe1, M. Diculescu1, B. Mateescu2, C. Cijevschi Prelipcean3, L. Gheorghe1

Created: Friday, 22 February 2019, 9:41 AM
P480: Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results From A Tertiary Inflammatory Bowel Disease Centre.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lim, C.T.(1)*;Tay, S.W.(1);Lim, G.H.(2);Salazar, E.(1);Ong, W.C.(3);Chan, W.P.W.(1);Tan, M.T.K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P481 Repeated surgery for recurrent ileocolonic Crohn’s disease: does the outcome keep worsening operation after operation? A comparative study of 1224 consecutive procedures
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Colombo1, A. Frontali1, C. Baldi1, G.M.B. Lamperti1, G. Maconi2, S. Ardizzone2, D. Foschi2, G. Sampietro1

Created: Thursday, 30 January 2020, 10:12 AM
P481: Effect of anti-TNFα therapy with daily physical activity in patients with Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

F. A. Lucca, C. Malaguti, A. L. Cabalzar, L. A. Chebli, T. C. R. Ribeiro*, P. D. Gaburri, J. M. F. Chebli

Created: Friday, 22 February 2019, 9:49 AM
P481: Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

Created: Friday, 22 February 2019, 9:41 AM
P481: Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project
Year: 2021
Source: ECCO'21 Virtual
Authors: Viola, A.(1);Barbieri , M.A.(2);Pisana, V.(1);Cutroneo , P.M.(3);Fries, W.(1);Spina, E.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P481: Induction treatment with subcutaneous rather than intravenous ustekinumab is associated with comparable circulating drugs levels and early clinical response
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.R. Rowan1*, G. Cullen2, H. Mulcahy2, J. Sheridan2,3, E. Ryan4, A. De Vries5, G. D'Haens6, G.A. Doherty2

Created: Thursday, 21 February 2019, 9:14 AM
P481: profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Suarez Ferrer, C.J.(1);Mesonero, F.(2);Caballol, B.(3);Ballester, M.P.(4);Baston Rey, I.(5);Castaño Garcia, A.(6);MIranda Bautista, J.(7);Saiz Chumillas, R.(8);Benitez, J.M.(9);Sanchez Delgado, L.(10);Lopez-Garcia, A.(11);Rubin de Celio, C.(12);Alonso Abreu, I.(13);Melcarne, L.(14);Plaza Santos, R.(15);Marques Cami, M.(16);Caballero Mateos, A.(17);Gomez Diez, C.(18);Calafat, M.(19);Alonso Galan, H.(20);Vega Vilaamil, P.(21);Castro Sensosian, B.(22);Guerro Moya, A.(23);Rodriguez Diaz, C.Y.(24);Spicakova, K.(25);Manceñido Marcos, N.(26);Molina, G.(27);De Castro, L.(28);Rodriguez Angulo , A.(29);Cuevas del Campo , L.(30);Rodriguez Grau, M.C.(31);Ramirez, F.(32);Gomez Pastrana, B.(33);Gonzalez Partida, I.(34);Botella Mateu, B.(35);Peña Gonzalez, E.(36);Iyo, E.(37);Elosua Gonzalez , A.(38);Mañosa Ciria, M.(39);Barreiro-De Acosta, M.(40);
Created: Friday, 11 February 2022, 3:56 PM
P481: Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different “therapeutic window” between post-induction and maintenance treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Feng T.1, Chen B.1, Mao R.1, Ben-Horin S.2, Chen M.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P481: Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tan, Z.(1)*;Chin, A.(2);Welman, C.J.(3,4);Thin, L.W.Y.(1,5);
Created: Friday, 14 July 2023, 11:05 AM
P482 Patient and physician perspectives on the management of inflammatory bowel disease: Disease remission and durability of treatment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Afzali1, A. Armuzzi2, Y. Bouhnik3, B. Bressler4, A. Hart5, D. Rubin6, M. Sans7, B. Siegmund8, C. Sninsky9

Created: Thursday, 30 January 2020, 10:12 AM
P482: Different characteristics of inflammatory bowel disease patients between tertiary referral centres and secondary hospitals
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. H. Song*1, Y. J. Lee2, K. O. Kim3, H. S. Lee4, E. S. Kim2, J. I. Koo1, J. S. Jeong1, W. S. Seo1

Created: Friday, 22 February 2019, 9:49 AM
P482: Early anti-TNF/immunomodulator therapy is associated with better clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Oh E.H.*1, Oh K.1, Seo H.2, Chang K.2, Kim G.-U.2, Song E.M.2, Seo M.2, Lee H.-S.3, Kwon E.J.2,4, Hwang S.W.2,4, Park S.H.2,4, Yang D.-H.2, Kim K.-J.2,4, Byeon J.-S.2, Myung S.-J.2, Yang S.-K.2,4, Ye B.D.2,4

Created: Wednesday, 20 February 2019, 10:36 AM
P482: Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project
Year: 2022
Source: ECCO'22
Authors: Colclough, J.(1);Ali, M.(2);Shami, N.(2);Aitchison, L.(2);Hurst, A.(2);Shams-Khan, H.(2);
Created: Friday, 11 February 2022, 3:56 PM
P482: Safety and efficacy of ustekinumab for Crohn’s disease in the elderly population
Year: 2021
Source: ECCO'21 Virtual
Authors: Fiske, J.(1);Liu, E.(2);Limdi, J.(2);Conley, T.E.(1);Townsend, T.(1);Davies, M.(3);Brockwell, R.(3);Baig, D.(1);Abdelbadiee, S.(1);Uney, A.(1);Liaros, A.(4);Gaba, W.(5);Smith, P.J.(1);Subramanian, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Ye*1, M. Chen2, X. Gao3, K. Wu4, Z. Ran5, H. Yang6, Z. Liu7, Q. Cao8

Created: Friday, 22 February 2019, 9:41 AM